Loading organizations...
§ Private Profile · Montreal, Canada
We teach your immune system to attack and cure cancer
Key people at Modulari-T.
Modulari-T was founded in 2021 by David White (Founder) and Stephanie Mok (Founder).
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.
Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.
Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Key people at Modulari-T.
Modulari-T is a pioneering biotech startup founded in 2021 that develops advanced cell therapies to teach the immune system to attack and cure cancer. Their flagship product is the MARC platform, a novel modular chimeric antigen receptor technology that reprograms immune cells, such as T cells and NK cells, to enhance potency and persistence while reducing side effects significantly compared to existing CAR-T therapies. Modulari-T serves cancer patients by addressing the limitations of current immunotherapies, aiming to provide safer, more effective, and more accessible treatments that could replace or reduce reliance on chemotherapy. The company is gaining momentum with preclinical validation and recognition in biotech hubs like Montreal and San Francisco, positioning itself to impact the rapidly growing cell therapy market projected to exceed $50 billion by 2030[1][2][3][4].
Modulari-T was founded in 2021 by David Cotnoir-White, Stephanie Mok, and Étienne Gagnon, a team combining expertise in protein engineering, synthetic biology, and immunology. The idea emerged from the need to overcome the high failure rates, safety concerns, and production inefficiencies of existing cell therapies. Early traction came from developing the MARC platform, which demonstrated twice the potency of CAR-T therapies with up to a 90% reduction in harmful side effects. Their innovative approach attracted attention within the Montreal biotech ecosystem and beyond, supported by incubators like District 3, helping establish Modulari-T as a promising player in next-generation immunotherapies[1][3].
Modulari-T is riding the wave of rapid advances in immunotherapy and synthetic biology, particularly the growing demand for safer, more effective cancer treatments. The timing is critical as the cell therapy market expands, with increasing investment and regulatory support for innovative therapies. Market forces such as rising cancer incidence, the limitations of chemotherapy, and the need for personalized medicine favor Modulari-T’s approach. By advancing modular, AI-designed immune receptors, Modulari-T influences the broader ecosystem by pushing the boundaries of cell and gene therapy, potentially enabling applications beyond oncology into autoimmunity and regenerative medicine[1][2][4].
Looking ahead, Modulari-T is poised to transition from preclinical to clinical stages, validating its MARC platform’s efficacy and safety in human trials. Trends such as AI-driven protein design, modular therapeutic platforms, and in vivo delivery methods will shape their trajectory. As they scale, Modulari-T could redefine cancer treatment paradigms, reduce healthcare costs, and expand cell therapy indications. Their influence is likely to grow as they contribute to the maturation of the biotech ecosystems in North America and beyond, fulfilling their mission to teach the immune system to attack and cure cancer with transformative precision and safety[1][4].
Modulari-T was founded in 2021 by David White (Founder) and Stephanie Mok (Founder).
